Description

Product Description

Retatrutide acetate, also known as LY3437943 acetate, is a synthetic triple agonist peptide that simultaneously activates the glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R). This unique pharmacological profile makes it one of the most advanced poly-agonist candidates in metabolic research.

Background in Obesity and Metabolic Research

Obesity and type 2 diabetes mellitus (T2DM) are global health challenges associated with insulin resistance, impaired glucose metabolism, and excessive fat accumulation. Traditional therapeutic approaches targeting a single receptor pathway (e.g., GLP-1R agonists like semaglutide) have demonstrated clinical benefit, but their efficacy may plateau due to compensatory metabolic mechanisms.

Poly-agonist peptides like Retatrutide acetate are designed to engage multiple complementary metabolic pathways, thereby enhancing efficacy in weight reduction, glycemic control, and energy balance.

Receptor Targets and Potency

• GCGR (Glucagon receptor): EC50 = 5.79 nM → stimulates energy expenditure and fat oxidation.

• GIPR (Glucose-dependent insulinotropic polypeptide receptor): EC50 = 0.0643 nM → promotes insulin secretion and nutrient handling.

• GLP-1R (Glucagon-like peptide-1 receptor): EC50 = 0.775 nM → enhances satiety, delays gastric emptying, and improves glycemic control.

Applications in Research

1. Obesity Research – evaluation of weight loss efficacy, energy expenditure, and fat metabolism.

2. Diabetes Research – studies on glycemic regulation, insulin secretion, and glucose tolerance.

3. Metabolic Syndrome Models – exploration of lipid metabolism, cardiovascular parameters, and hepatic function.

4. Poly-Agonist Peptide Development – model compound for next-generation anti-obesity peptides.

5. Comparative Pharmacology – studied alongside semaglutide, tirzepatide, and other incretin-based therapeutics.

Advantages of Retatrutide Acetate

• Triple-receptor agonism for synergistic metabolic benefits.

• Nanomolar potency ensures strong biological responses at low concentrations.

• Research utility in both in vitro receptor signaling assays and in vivo obesity/diabetes models.

In summary, Retatrutide acetate represents a promising next-generation poly-agonist peptide, providing researchers with a unique tool to study the interplay of incretin and glucagon pathways in obesity and metabolic disorders.

Product Specifications

Extended Notes

• Triple receptor agonism differentiates Retatrutide acetate from single-pathway incretin drugs.

• Stability enhanced by acetate salt form for laboratory handling.

• Applications include animal models of diet-induced obesity, insulin resistance, and glucose metabolism studies.

Mechanism of Action

Retatrutide acetate achieves its effects by simultaneously activating three metabolic receptors, producing a synergistic modulation of energy balance, glucose metabolism, and appetite regulation.

Stepwise Mechanism

1. Activation of GCGR (Glucagon Receptor):

   • Stimulates hepatic glucose output and lipid oxidation.

   • Enhances energy expenditure, contributing to weight loss.

2. Activation of GIPR (Glucose-Dependent Insulinotropic Polypeptide Receptor):

   • Increases glucose-dependent insulin secretion.

   • Improves postprandial glucose tolerance.

3. Activation of GLP-1R (Glucagon-Like Peptide-1 Receptor):

   • Enhances satiety and reduces food intake.

   • Slows gastric emptying, improving glycemic excursions.

   • Provides cardioprotective benefits in research models.

Synergistic Effects

By targeting three complementary pathways, Retatrutide acetate produces a greater weight reduction and metabolic improvement compared to GLP-1R agonists or dual agonists alone.

Research Implications

• Model compound for poly-agonist drug design.

• Valuable in studying energy balance and obesity pathophysiology.

• Helps explore mechanistic differences between single, dual, and triple agonist peptides.

  

Side Effects (Research Context)

In preclinical and early clinical studies, the following observations have been made regarding peptides with Retatrutide’s mechanism:

1. Gastrointestinal Disturbances – nausea, vomiting, and diarrhea due to GLP-1R activation.

2. Transient Hypoglycemia – when combined with other insulinotropic compounds.

3. Increased Heart Rate – observed in some incretin/glucagon receptor agonists.

4. Injection Site Reactions – mild erythema or swelling.

5. Hepatic Enzyme Changes – related to GCGR activation in animal models.

Note for Research Use: These findings highlight the importance of dose optimization and receptor-specific profiling when studying Retatrutide acetate in experimental models.

Disclaimer

This product is intended for research use only. Not for human administration or therapeutic purposes. All information is provided for scientific and educational research.

Keywords

Retatrutide acetate, LY3437943 acetate, CAS Retatrutide, GCGR agonist, GIPR agonist, GLP-1R agonist, triple agonist peptide, obesity research peptide, diabetes research peptide, metabolic disorder research compound.